Potential use of lenvatinib for patients with unresectable hepatocellular carcinoma beyond progression of sorafenib treatment: A real-world evidence and in vitro assessment with protein phosphorylation array.

Yasushi Sato,Tetsu Tomonari,Hironori Tanaka,Takahiro Tanaka,Akihiro Hirao,Koichi Okamoto,Hiroshi Miyamoto,Naoki Muguruma,Harumi Kagiwada,Masashi Kitazawa,Kazuhiko Fukui,Katsuhisa Horimoto,Tetsuji Takayama

Potential use of lenvatinib for patients with unresectable hepatocellular carcinoma beyond progression of sorafenib treatment: A real-world evidence and in vitro assessment with protein phosphorylation array.

2020

Yasushi Sato
Tetsu Tomonari
Hironori Tanaka
Takahiro Tanaka
Akihiro Hirao
Koichi Okamoto
Hiroshi Miyamoto
Naoki Muguruma
Harumi Kagiwada
Masashi Kitazawa
Kazuhiko Fukui
Katsuhisa Horimoto
Tetsuji Takayama

485Background: No information is available on the efficacy and safety of lenvatinib (LEN) as a second/third-line treatment for unresectable hepatocellular carcinoma (HCC) after sorafenib (SOR) ther...

Keywords:

Hepatocellular carcinoma
Lenvatinib
Cancer research
Sorafenib
Medicine
Protein phosphorylation
Pathology
In vitro
Oncology
real world evidence
sorafenib treatment
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations